Reactive Biosciences utilizes boron-based compounds to discover and develop medicines targeting historically undruggable diseases. The platform aims to create impactful therapies that can significantly improve patient outcomes in challenging medical areas.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are considered "undruggable" due to the lack of effective drug targets or the inability of traditional drug molecules to interact with these targets. This limitation leaves patients with few or no treatment options for these challenging medical conditions.
Solution
Reactive Biosciences leverages the unique chemical properties of boron to design and develop novel therapeutics that can address previously undruggable diseases. Their platform focuses on creating boron-based compounds that can selectively bind to and modulate difficult-to-target proteins or biological pathways. By harnessing the distinct characteristics of boron, Reactive Biosciences aims to create impactful medicines that can significantly improve patient outcomes in areas where current treatments are inadequate.
Target Audience
The primary target audience includes patients suffering from diseases with limited or no effective treatment options, as well as pharmaceutical companies seeking innovative approaches to address historically undruggable targets.
Features
- Boron-based compound library with diverse structural and functional properties
- Proprietary screening assays to identify boron-containing molecules with desired target engagement and activity
- Medicinal chemistry expertise to optimize boron-based compounds for improved potency, selectivity, and drug-like properties
- In vivo pharmacology studies to evaluate the efficacy and safety of boron-based therapeutics in relevant disease models